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1. Introduction 
Lymphedema is the result of an abnormality of the lymphatic system. It is caused by an 
excessive accumulation of lymphatic fluid, known as interstitial fluid, in the interstitial 
tissue, particularly in the subcutaneous fat. Ultimately, this leads to swelling of affected 
tissues due to a build up of and inadequate lymph drainage, known as lymphedema 
(Farrow, 2010a) [Figure 1]. 
  
Fig. 1. Right arm lymphedema 
Primary lymphedema occurs when people are born with abnormalities in the lymphatic 
system, such as missing or impaired lymphatic vessels (Farrow, 2010b). The severity of the 
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condition is able to assess whether swelling is present at birth or develops at the onset of 
puberty or in adulthood. It can affect from one up to four limbs and/or body parts (Farrow, 
2010a). Secondary lymphedema is more common and occurs from damage to the lymphatic 
system that occurs as a result of cancer and its treatment, due to the resection of lymph 
nodes. Trauma to the skin, such as burns or infections, can also cause secondary 
lymphedema (Gordon, 2007; Piller, 2009). 
Signs and symptoms of progressive lymphedema include discomfort and pain associated 
with full sensation in the limb(s) and the skin feeling tight, as well as difficulty with daily 
tasks due to a decreased flexibility in the hand, wrist, or ankle and the inability to fit into 
clothing and jewelry in a certain area. Progressive lymphedema is complicated by recurrent 
infections, non-healing wounds, as well as emotional and social distress (Ridner, 2009; 
Ahmed, 2008; Shih, 2009).  
Lymphedema is prevalent and most often studied as a consequence of breast cancer. 
However, it has been studied in cases of melanoma, gynecological cancer, head and neck 
cancer as well as sarcoma (Lewin et al., 2010; Murphy et al., 2010; Smith et al., 2010; Cormier 
et al., 2010; Lacomba, 2010). Research shows that there is a lifelong risk of developing 
lymphedema due to cancer and the overall risk has been reported to be 15.5% (Chang et al., 
2010)  [Figure 2]. 
 
Fig. 2. A woman with locally advanced breast cancer status post left modified radical 
mastectomy and lymph node dissection and radiotherapy to the left chest wall, 
supraclavicular area and axillary lymph nodes. A. Left arm at 3 months after treatment. B. 
Left arm demonstrates marked lymphedema at 3 years after treatment. 
A B
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Both primary and secondary lymphedemas possess characteristic features that can be 
distinguished over time. History should include information such as age of onset, location(s) 
of swelling, pain and other symptoms of discomfort, medications that instigate swelling, the 
course of progression of swelling, and factors prompting swelling such as cancer, injury, or 
infection. Family history is important to diagnose inherited forms of lymphedema (Gupta, 
2006). A physical examination assesses the vascular system, the soft tissue and skin 
surrounding the swollen body parts, palpation of lymph nodes, and looks for changes in the 
body systems in accordance with inherited lymphedemas (Wang, 2005; Moseley et al., 2008). 
Further diagnostic tests and imagining coupled with history, family history, and physical 
examination are used to correctly diagnose a patient (Lewin et al., 2010; Smith et al., 2010).  
Lympehedema is a type of side effect requiring attention to diagnosis and management by a 
number of specialists taking care of a patient with breast cancer.  It is critical for each 
discipline to pay particular attention to the patients’ subjective reporting of their symptoms 
suggestive of lymphedema.  Therefore, a multidisciplinary approach to diagnosis and 
management of lympehedema is essential for the routine surveillance after treatment by all 
the involved physicians, including the surgeon, radiation oncologist, and medical 
oncologist. A lymphedema specialist’s consultation is often necessary, especially when the 
patient is at risk for developing lymphedema or has an evidence of this diagnosis on 
physical examination.  
2. Diagnosis of lymphedema 
Physical examination includes placing hands on location of lymphedema and feeling 
palpation as well as the surrounding area of the affected limb. This procedure is called 
subjective palpation.  Upon physical examination, the standard way of detecting 
lymphedema is by taking measures of limb volume (Chen et al., 2008; Cheville et al., 2003; 
Hayes et al., 2005). An enlargement, or increase in volume, of the limb is the result of fluid 
build up in the tissues. Volume is measured by 3 methods including tape measurements, 
perometry, and water displacement. These measurements of volume illustrate the presence 
and severity of the condition (Unno et al., 2008). Tape measurements are most accurate 
when done at precisely defined intervals and when taken by the same individual, ultimately 
using geometric formulas to determine the total volume.  
Perometry uses an infra-red optical electronic scanner to calculate volume by precisely 
positioning the body part exactly the same each time and calibrating the machine (Rockson 
et al., 2007). This method can detect volume changes in breast cancer survivors as little as 3% 
(Czerneic et al., 2010). Water displacement measurements are taken by immersing the limb 
in a large cylinder and determining the volume of water displaced, or pushed out of the 
cylinder. However, measuring volume cannot differentiate lymphedema from other types of 
edema and is a technique best used as follow up for treatment of lymphedema rather then 
diagnosis (Unno et al., 2008). 
A radiological technique, that detects slow or absent lymph flow and areas of reflux or 
backup of lymph node and lymph vessel imaging due to lymphedema is called a 
lymphoscintigraphy. Normally, technetium labeled sulfur is the radio-labeled particle of 
protein injected directly under the skin to detect and image the affected area (Piller, 2009; 
Szuba et al., 2003; Hayes et al., 2008; Bellini et al., 2005). The procedure identifies lymphatic 
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problems at late stages of lymphedema and shows the basics of the peripheral lymphatic 
system and larger more prominent lymph nodes and vessels. Radiology dpartments are apt 
at performing lymphoscintigraphy studies aimed at identifying the sentinel lymph node for 
cancers of the breast and ultimately further studies for the diagnosis of lymphedema 
Cornish et al., 2007; Szuba et al., 2000, 2003, 2007) 
A more recent technique of lymph vessel imaging uses indocyanine green (ICG) injections 
into the skin and an infrared fluorescence camera to detect the function of even the smallest 
lymphatic vessels. This is called Near Infra‐Red Florescence Imaging (NIR). NIR-ICG can 
pick up early stages of lymphedema and diagnose diseased non-contracting lymphatics 
even before swelling occurs (Farrow, 2010; Adams et al.; Rasmussen et al., 2009, 2010; Unno 
et al., 2010; Maus, 2010) 
There is a variety of diagnostic tests that can be performed in order to classify and detect 
lymphedema. These include soft tissue imaging, bioimpedance spectroscopy, tonometry, 
genetic testing, various forms of vascular imaging, as well as blood tests (Farrow, 2010).  
Soft tissue imaging like MRIs (magnetic resonance imaging), CTs (computed tomography 
scans, and US (ultrasounds) detect excess fluid in the tissues. Since lymphedema is the result 
of interstitial fluid build up these imaging techniques are often used to determine the cause 
of the condition as well as lymphedema that is a result of an untreated cancer (Astrom et al., 
2001; Deltombe et al., 2007; Unno et al., 2008) 
Bioimpedance Spectroscopy (BIS) measures water content in tissues by passing a small, 
harmless, electrical current through the limb in order to measure the impedance to current 
flow. The higher the water content in the area the lower the resistance. BIS assesses the 
condition by comparing the resistance of electrical flow in the intracellular and interstitial 
fluid of a whole limb, because calculations are performed to the length of the body part 
(Gergich et al., 2008; Ward, 2006; Rockson et al., 2007). 
Lymphedema is graded according to increased size as well as staging of the progression in 
the change of the skin texture. As a consequence lymphedema the skin and subcutaneous 
tissue become harder and denser (Executive Committee of International Society of 
Lymphology, 2009). Upon physical examination, tissue texture, pitting, larger skin folds, 
wounds or papillomas are noted. Current examinations to determine skin texture and 
resistance are tissue dielectric constant and tonometry. The tissue dielectric constant 
measures tissue water content and uses a specific frequency of an electrical current to 
measure the reflected return wave in order to indicate how much water is present in the 
tissue (Mayrovitz, 2009; Corica et al., 2006; Mirnajafi et al., 2004; Ridner et al., 2007). 
Tonometry determines how firm a tissue is by measuring how much force is needed to 
indent the tissue sample (Mayrovitz, 2009) [Figure 3]. 
Young patients diagnosed with primary lymphedema should undergo genetic testing and 
counseling and have a karyotype test performed in order to detect abnormalities. Turner’s 
syndrome has been linked to lymphedema and can be determined from a karyotype. 
Specific genes are also associated with lymphedema (Ferrell, 2008). These include FOXC2 an 
SOX18 (Connell et al., 2009; Brice et al, 2002). However, inherited lymphedema is not 
detectible on gene or chromosome tests and genetic testing for late-onset lymphedema does 
not prove to have benefits (Farrow, 2010b).  
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Fig. 3. A tonometer is used to assess the firmness of a tissue by measuring how much force 
is needed to indent the tissue sample. 
Cardiovascular diseases or abnormalities may also serve as a trigger for many forms of 
edema (Schumacher et al., 2008). For those given a diagnosis of primary lymphedema, it is 
important to determine if congestive heart failure, deep venous thrombosis, damaged 
valves in the vein or any arterial conditions account for the swelling or are an adjunct to 
existent lymphedema (Szuba, 2000; Bellini, 2005). Secondary lymphedema, as a result of 
cancer, can be studied by taking images of the heart, veins and valves to determine the 
case, severity, and treatment options of the edema. Cardiovascular studies usually 
ordered for edema studies include echocardiogram, venous ultrasound, and arterial 
ultrasound with ankle brachial index (ABI). It is best to do ultrasounds in a standing up 
position to test for incompetency of the valves. More advanced forms of imaging for 
insufficiency of blood vessels is by means of a computed tomography, venogram, and 
arteiogram. These are normally used to assess conditions in the chest, abdomen, or pelvis 
(Farrow, 2010).   
Blood tests are unavailable for diagnosis of lymphedema. However, conditions that mimic 
lymphedema’s symptoms such as hypothyroidism or hypoproteinemia may cause swelling 
and need to be assessed by means of a blood test. For some lymphedemas that are 
genetically inherited x-rays are important to detect orthopedic abnormalities (Bellini et al., 
2009; Gupta et al., 2006). 
3. Lymphedema as a long-term sequelae of breast cancer therapy 
There are recommended guidelines to follow for optimal prevention, screening and 
measurement for early detection of breast cancer related lymphedema (Farrow, 2010c). 
There should be a pro-active approach pre-operatively and post-operatively for arm 
measurements taken by patients and physicians. Patients should receive risk‐reduction 
strategies prior to treatment (NLN Position Paper, 2011; Fu et al., 2010). Weight and 
height should be accurately measured during each visit to a specialist in order to 
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determine body mass index (BMI). A BMI greater than or equal to 25 warrants a 
consultation with a dietician and a BMI greater or equal to 30 warrants a consultation 
with a dietician and a weight reduction (Ridner et al., 2011; Helyer et al., 2010; Centers for 
Disease Control, 2011). 
Patients that have been diagnosed with breast cancer should have baseline pre and post-
treatment arm measurements taken on both arms and should be given this information to 
share with other healthcare providers. Lymphedema warrants active surveillance post-
treatment for such symptoms as swelling, heaviness or tightness in the affected arm(s), and 
at‐risk chest and truncal areas. If there appears to be an increase of 1 cm in any of the 
circumference measurements when compared to the contralateral limb, the patient should 
schedule a follow‐up visit in 1 month. A 2 cm change in any of the circumferential 
measurements or a 5% volume change in an at‐risk limb warrant immediate referral for 
further evaluation by a professional trained in lymphedema assessment and management. 
Subjective symptom reports should be taken seriously and may include perceived swelling, 
tightness, tingling, and heaviness (Farrow, 2010c). 
Surgical techniques of managing breast cancer and long-term morbidity include radical 
mastectomy, modified radical mastectomy, and lumpectomy. Surgical approaches to 
axillary treatment include sentinel lymph node dissection (SLND) and axillary lymph node 
dissection (ALND). The number of lymph nodes that defines ALND is 10, and the standard 
ALND involved at least dissection of levels I-II axillary lymph nodes, based on the 
arbitrarily set anatomic Berg principles (Berg, 1955). Identification of a sentinel lymph node 
for SLND is typically done by either an injection of the isosulfan blue dye, the technetium 
(99mTc)-sulphur colloid, or both. All blue-stained nodes and/or nodes with radioactive 
counts, as measured with the gamma probe, are defined as sentinel lymph nodes. Typically, 
the number of nodes sample as a result of a SLND is small, with a median number of 2 
nodes (Wernicke, 2010). 
A number of efforts have been employed to minimize the risk of lymphedema (Figure 2B), 
as it is associated with the dissection of a large number of axillary lymph nodes.  Various 
studies have determined the incidence of lymphedema depending on the type   of lymph 
node dissection, ALND versus SLND.  Table I summarizes the incidence of lymphedema 
based on the type of axillary lymph node surgery – SLND or ALND – from a number of 
published studies for both node negative and node positive patients. The Milan trial, the 
Sentinella/GIVOM trial, The ALMANAC-UK trial, and the NSABP B-32 trial all showcase 
node negative patients in the varying prospective randomized trials (Veronesi et al., 2003, 
1997; Land et al., 2010; Mclaughlin et al., 2008; Ashikaga et al., 2008; Mansel et al., 2006). 
In the Milan Trial, at the median follow up of 3 years lymphedema, as assessed by a 
medical professional, was detectable in 7/100 (7%) of patients in the SLND group in 
contrast with 75/100 (75%) of cases of lymphedema in the ALND group (Veronesi et al., 
2003, 1997). In the Sentinella/GIVOM trial, it was found that the odds ratio of sentinel 
lymph node to axillary lymph node was 0.52 at their median follow up of 4.6 years (Land 
et al., 2010). In the ALMANAC-UK trial, with a short median follow up of 1 year 
lymphedema was assessed by a patient and was reported in 20/412 (4.9%) of patients in 
the SLND group in contrast with 53/403 (13%) of cases of lymphedema in the ALND 
group (Mclaughlin et al., 2008).   
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Published 
studies 
Median 
follow 
up 
(years) 
N 
Inclusion 
Criteria 
Lymphedema by 
medical 
professionals (%) 
Lymphedema 
by patients 
(%) 
MILAN 
(Veronesi et al., 
1997, 2003) 
(negative SLN in 
341patients 
(167SLN 
+174ALND) 
(1998-1999) 
3 516 
<2cm, L 
only (wide 
excision or 
quadran-
tectomy) 
* 7/100 (7) 
# 75/100 (75) 
N/A 
Sentinella/ 
GIVOM 
(Land et al., 2010) 
(1999-2004) 
4.6 749 
<3cm, 
L,MRM 
0.522 N/A 
ALMANAC-UK 
(Mclaughlin et al., 
2008) 
(1999-2003) 
1 1031 
<2, 2-5,>5cm, 
L, MRM, 
axillary RT 
N/A 
* 20/412 (5) 1 
# 53/403 (13) 1 
ACOSZOG Z0011 
Trial (Aareleid et 
al., 2002) 
(1999-2004) 
3 891 
<2cm, L, with 
1-2 +SLN 
* 14/226 (6) 
# 26/242 (11) 
* 14/253 (5) 
# 52/272 (19) 
NSABP B-32 
Morbidty results 
(Ashikaga et al., 
2010) 
(1999-2004) 
3 5611 
≤2.0, 2.1-4.0, 
>4.0 cm, L or 
M 
*303/1459 (20.8) 
# 431/1421 (30.3) 
N/A 
NSABP B-32 
Outcome study 
(Mansel et al., 2006) 
(2001-2004) 
3 749 
≤2.0, 2.1-4.0, 
≥4.1 cm, L or 
M 
N/A 
*10/320 (3) 
# 25/307 (8) 
Wernicke et al. 
(Wernicke et al., 
2010, 2011) 
10 265 <5.0cm, L 
*6/111 (5.4) 
#21/115 (18.3) 
* 10/111 (10.0) 
# 39/115 (33.9) 
L=lumpectomy 
MRM=modified radical mastectomy 
RT=radiotherapy 
*SLND=Sentinel Lymph Node 
# SLN +ALN=Sentinel Lymph Node+Axillary Lymph Node 
1 Summation of patients with mild and severe symptoms. 
2 Odds ratio (SLN/ALN)  
Table 1. A summary of incidence of lymphedema from the published studies. 
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In the NSABP B-32 trial, at a 3-year follow-up lymphedema was assessed by both medical 
professionals and by patients themselves. When assessed by the former, the incidence of 
lymphedema was 303/1459 (20.8%) of patients in the SLND group in contrast with 
431/1421 (30.3%) of cases of lymphedema in the ALND group. However, the patient self-
assessment group demonstrated the rate of lymphedema as 10/320 (3.1%) in the SLND 
cohort and occurred in 25/307 (8.1%) of women in the ALND group (Ashikaga et al., 2008; 
Mansel et al., 2006). One of the largest retrospective reviews of a mature 10-year follow-up 
of experience from Thomas Jefferson University Hospital conducted by Wernicke et al, 
also assessed lymphedema by two methodologies. It was evident that regardless of 
whether the assessment was performed by a medical professional or a patient, there was 
statistically significant difference in the rates of this complication between the two cohorts 
as experienced by patients.  When assessed by a medical professional, lymphedema was 
detectable in 6/111 (5.4%) of patients in the SLND group in contrast with 21/115 (18.3%) 
of cases of lymphedema in the ALND group, respectively (p<0.0001). The patient self-
assessment groups demonstrated the lymphedema in 10/111 (10.0%) of patients in the 
SLND cohort and 39/115 (33.9%) of women reporting this complication in the ALND 
group (p<0.0001). This difference appears to be sustainable even a decade after the 
surgery, and the percentage of patients that experienced chronic lymphedema is 
significantly greater in the ALND cohort as compared with the SLND one (Wernicke et 
al., 2010) [Table 1].  
The ACOSOG Z001 trial assessed patients with clinically positive axillary nodes (Aareleid et 
al. 2002). In this study, lymphedema was also assessed by the dual methodologies of a 
medical professional and a patient self-assessment. At a median follow-up age of 3 years, 
when assessed by a medical professional, lymphedema was detected in 14/226 (6%) of 
patients in the SLND group in contrast with 26/242 (11%) of cases of lymphedema in the 
ALND group. The patient self-assessment groups demonstrated the incidence of 
lymphedema in 14/253 (5%) of patients in the SLND cohort and 52/272 (19%) of women 
reporting this complication in the ALND group [Table I]. 
Could radiotherapy be a contributing factor to the complications of axillary surgery? If a 
low incidence of ALN failures lies in sterilization of the occult metastases in the axillary 
lymph nodes with the conventional breast tangential ports delivering RT to a patient in a 
supine position (Wernicke et al., 2010), radiotherapy may be at least in part responsible 
for the morbidity attributable to surgery. Goodman et al reported that with the standard 
radiation tangents, 90% of the Berg level I axilla and up to 70% of level II axillary lymph 
nodes received 95% of the prescribed dose to the breast (Smitt et al., 1999). Figure 4 
demonstrates a typical patient treated with 3-D radiotherapy in the supine position with 
the standard tangential radiation fields targeting the breast tissue and inadvertently 
providing at least partial coverage for at least two of the Berg axillary levels. The vast 
majority of literature, with only a few negative studies, supports the fact that the modern 
3-D tangential radiation port of the breast, administered in supine position, will at least 
partially irradiate the undissected axillary lymph nodes stations (Smitt et al., 1999; Takeda 
et al., 2000, 2004; Krasin et al., 2000; Aristei et al., 2001; Schlembach et al., 2001; Orecchia 
et al., 2005; Wong et al., 2008; Rabinovitch et al., 2008). This phenomenon may explain 
why even patients with SLND experience lymphedema as a long-term toxicity [Wernicke 
et al., 2010].   
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Fig. 4. A. A relationship between local breast tangent radiation field and regional lymph 
nodes as depicted in the lateral beam’s eye view with a tangential portal, where the superior 
border of the radiation portal is set below the heads of the clavicles (navy). B. The axial 
image through the dissected axilla demonstrates Level I (blue), Level II (purple), and Level 
III (dark green) axillary lymph nodal stations which are partially covered by the 90% 
isodose area covering the breast tissue (orange).  
Does lymphedema have any risks associated with the use of systemic therapy? No 
significantly increased risk of incidence of lymphedema was observed in the literature with 
systemic therapy using hormonal treatment (Norman et al., 2010). Chemotherapy has been 
reported in some series to increase the complication rate associated with breast RT, 
including arm edema (Meek, 1998). However, no formal studies report any concrete data, 
which can predict such outcomes. 
4. Treatment of lymphedema 
4.1 Non-invasive management techniques 
The main, “gold standard” of treatment for lymphedema is Combined, Complex or 
Comprehensive Decongestive Therapy (CDT) (Mayrovitz, 2009). The initial reductive phase of 
CDT treatment is known as Phase I. The main goals are to reduce the size of the affected 
location and to improve the skin. Phase II is known as the maintenance phase, where the patient 
self-manages to keep the effects of phase I treatment long term (Szuba, 2000; Hinrichs et al., 
2004; Lasinski, 2002; Thomas et al., 2007; Koul et al., 2007). The effects of CDT include decreases 
in swelling, an increase in lymph drainage from the congested areas, a reduction in skin fibrosis 
and improvements in the skin conditions, an enhancement in the patient’s functional status and 
quality of life as well as a relief in discomfort, and a reduced risk of cellulitis and Steward-
Treves-Syndrome (a rare form of angiosarcoma) (Hammer et al., 2007; Mondry et al., 2004; 
Ferrandez, 1996; Franzcek et al., 1997; Hayes et al., 2008; Ahmed, 2008; Weiss, 2002; Kim et al., 
2007; Cormier et al., 2009; Hormes et al., 2010; Fu et al., 2009; Vignes, 2006). 
Components of Combined, Complex or Comprehensive Decongestive Therapy include 
manual lymph drainage (MLD), multi-layer, short-stretch compression bandaging, 
lymphatic exercise, skin care, and education in lymphedema management as well as elastic 
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compression garments (Didem et al., 2005; Ko, 1998). There are to phases of CDT: Phase I 
(Reductive) and Phase II (Maintenance). The first phase’s frequency and duration should be 
altered as to produce the best possible outcome of improvements in skin and reduction in 
swelling of the affected area in the shortest time period. Normally, CDT is completed within 
3 to 8 weeks and administered daily, or 5 days per week (Mayrovitz, 2009; Ko, 1998; 
Yamamoto et al., 2008). The second phase of CDT is a self-management program is set up 
directly following completion of phase I. It includes self-lymph drainage, home lymphatic 
exercises, a skin regimen, and self-application of compression garments or bandages 
(Yamamoto, 2008). Phase II must be monitored and changed periodically to ensure 
effectiveness. This includes changing compression garments every 4-6 months and 
equipment replacements and maintenance. Monitoring by a medical profession is, also, 
essential to the long-term success for lymphedema treatment (Ko, 1998; Hafner et al., 2005; 
Boris et al., 1994; Johnstone et al., 2006; Lasinski, 2002).  
Therapists providing CDT care are recommended by the Lymphology Association of North 
America® (LANA®) to have a minimum of 135 hours of training. Additional training may 
be required for specialists treating facial, truncal, and genital lymphedema and patients with 
complex diseases or illnesses (Farrow, 2010b; Czerneic et al., 2010).  
Manual lymph drainage is a manual, hands-on, part of CDT care that prompts superficial 
lymphatic vessels to remove excess interstitial fluid which is then moved through the 
subepidermal fluid channels formed as a result of damage of the lymphatics (Williams et al., 
2002). Certified Lymphedema therapists use the MLD technique to stimulate fluid removal 
from areas where the lymphatics are not working properly into working lymph vessels and 
nodes (McNeely, 2004). 
Compression bandaging creates gradient compression by effectively utilizing multiple 
layers of several materials. Components of compression bandaging include tubular bandage 
lining, digit bandages, polyester, cotton, or foam under-cast padding, and multiple layers of 
short-stretch bandages with 50% overlap and 50% stretch to cover the entire limb. Short-
stretch bandages stretch to 40-60% from resting length and long-stretch bandages stretch to 
greater than 140% of resting length. Short-stretch bandages are applied with low to 
moderate tension and are more prominent at the ends of extremities, reduce tissue 
hardening, also known as fibrosis (Farrow, 2010b; Brice et al., 2002; King, 2001; Williams, 
2005; Lerner, 2000; Foldi et al., 2005) 
Exercise, including lymphatic “Remedial Exercise”, has been shown to have increased 
beneficial effects for patients with lymphedema. Patients are encouraged to create 
individualized exercise programs with a lymphedema specialist (Schmitz et al., 2009; 
Johansson et al., 2005; Mustian et al., 2009). Exercise must be done while wearing a 
compression garment or bandage to alleviate the build up of interstitial fluid (Gultig, 2005).  
Hygiene is an important factor in lymphedema treatment which aides in reducing the 
amount of fungus and bacteria present on the skin. Cracks and dry skin are entry points for 
these pathogens and it is recommended that patients use low pH moisturizers to hydrate the 
skin and alleviate drying and cracking, which can lead to infections and wounds (Vaillant, 
2002; Mallon, 1994). Typical infection of the skin is known as cellulitis and, ultimately, 
requires antibiotic treatment in people with lymphedema (Czerneic et al., 2010; Al Niaimi et 
al., 2009; Cooper et al., 2009; Godoy et al., 2007).  
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After maximal volume reduction in Phase I CDT, patients will be fitted to any one of the 
following compression garments, depending on the affected body part: sleeves, stockings, 
bras, compression shorts, or face and neck compression wear. The patient will receive two 
compression garments one to wear and one to wash and dry. This is done to prevent 
wearing dirty or wet compression wear, which will promote growth of fungus and bacteria. 
Garments should be washed daily and replaced every 4-6 months to maintain the same 
compression strength. It is important the garment be properly fitted to the proper garment 
style and compression strength to maintain long-term control of the lymphedema in terms 
of volume control and skin health. Custom garments are made for those patients who 
cannot fit into ready-made garments and allow for special options such as reduction of risk 
of breakdown of skin or fastening devices for easier removal or putting on of the garment. 
There are both day and night or advanced day garments (Yasuhara, 1996; Badger et al., 2000; 
Cornu‐Thenard et al., 2007). The latter come in specialized varieties that better help to 
maintain the results of Phase I CDT, throughout Phase II. These include Velcro closure and 
specialized foam compression garments (Lund, 2000; Hafner et al., 2005; Lawrence, 2008).  
Seeing that lymphedema is a life-long condition, maintenance is very important (Fu et al., 
2008). Self-care includes education on risk-reduction practices, self-lymph drainage, skin 
care, signs and symptoms of infection, proper fit and care of garments, and the importance 
of good nutrition, as well as healthy regiments of exercise and weight control (Farrow, 
2010b). The risk of getting lymphedema increases with obesity. Therefore, it is important to 
maintain or lose to be at a normal, healthy weight (Gur et al., 2009; Petrek, 2001; Soran et al., 
2006; Helyer et al., 2010). It has been proven that the arm volume of post-mastectomy 
lymphedema patients decreases in overweight patients with weight loss (Shaw et al., 2007). 
Other patient conditions, such as scars, musculoskeletal ailments, palliative care necessities, 
post-radiation fibrosis, may require alterations in the CDT program. Adaptations are 
additions to CDT and include therapy, scar massage or myofacial therapy (Lund, 2000; 
Mallon, 1994; Yamamoto et al., 2008)  
Compression pump therapy or Intermittent Pneumatic Compression Therapy (IPC) can be 
used as either an adjunct to Phase I CDT or as a component of Phase II CDT. These pumps 
should have a individualized pattern of a multi-chamber system that stimulates lymph 
flow in a single direction based on the pattern and diagnosis of lymphedema. Since 
lymphedema is a result of a condition in a quadrant of the body as well as the limb, the 
pump must work to treat the condition as a whole (Shaw et al., 2007; Miranda et al., 2001; 
Yamazaki, 1988; Dini, 1998; Partsch, 1980; Hammond et al., 2009; Ridner et al., 2008; 
Szolnoky et al., 2009). Normal pump pressures range between 30-60 mmHg (Olszewski, 
2009). Recent studies show possible false correlations between the skin and device 
interface pressure patterns. This may have an ultimate effect on therapy (Mayrovitz, 
2007). Higher pressures are more dangerous because they may do harm to superficial 
structures (Segers et al., 2002). The length of treatment is normally 1 hour (Hammond et 
al., 2009; Ridner et al., 2008).  
Patients considered for IPC therapy need to be evaluated by a physician with medical 
knowledge of lymphedema. The evaluation provides level of pain and skin sensitivity as 
well as pressure for application to fibrotic areas. With trunk, chest or genital swelling is 
present, the physician must determine whether a pump that provides appliances to treat 
those areas is necessary or if the patient can manage the trunk swelling through self‐MLD or 
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garments. If a pump with only extremity attachments used, monitoring of a condition 
known as fibroscelerotic ring should be a must, to detect an increase in hardening of the 
tissue or edema above the device sleeve (Boris, 1998). If this occurs both the extremities and 
the trunk should be treated (Olszewski, 2009, Brice et al. 2002). 
IPC should not be administered with the following conditions: acute infection, severe 
arterial vascular disease, acute superficial or deep vein phlebitis (inflammation or clot), 
recurrent cancer in the affected area, or uncompensated congestive heart failure (Farrow, 
2010b). 
5. Invasive management techniques 
Surgical treatment for lymphedema is performed under special circumstances, when the 
condition’s severity supersedes all possible treatment options to control it, and in unison 
with CDT. Surgery has been used to reduce the weight of that part of the body that suffers 
from the condition, minimize the recurring inflammatory attacks, improve aesthetics, and to 
fit the limb into garments (Gloviczki, 1999; Vignes, 2002). Several surgical options have 
proven to work on lymphedema patients including debulking and liposuction, tissue 
transfers and microsurgical lymphatic reconstruction. Debulking surgery aims at removing 
hard connective tissue as well as large folds of fatty tissue that presents as a consequence of 
the condition. After this operation patients must wear compression garments to maintain 
the after effects of surgery, which include lymphatic scarring and lymphatic insufficiency. 
However, prolonged hospitalizations, poor healing of wounds, nerve damage or loss, 
intense scarring, negative effects on lymphatic vessels in that limb’s area, aesthetically 
displeasing results, and even loss of function in the limb may occur (Farrow, 2010b; Miller, 
1998; Salgado et al., 20009; Kim, 2004). 
Liposuction, performed under general anesthesia, is the removal of fatty tissue deposits and 
the creation of many small incisions in the affected body part withstanding a long history 
with the lymphedema condition. The fat is suctioned out by means of tubular suction 
devices which breaks up and liquefies it. Tight bandaging is necessary post surgery to stop 
bleeding and compression garments are worn life-long to prevent lymphedema recurrence 
due to possible scarring of the lymph vessels during the procedure. Bleeding, infection, skin 
loss, unordinary sensations, and recurrence may occur post-operatively (Brorson, 2003; 
Brorson et al., 2006; Fazhi et al., 2009). Tissue grafts, or tissue transfers, are less well known 
forms of surgery for effectively treating lymphedema. Their overall goal is to bring lymph 
vessels into congested areas for better removal of excess interstitial fluid (Fazhi et al., 2009; 
Slavin et al., 1999)  
Microsurgical and supramicrosurgical treatments, similarly aim at draining excess 
lymphatic fluid by means of shuttling lymph vessels to more congested areas. Although no 
long-term studies have been conducted on the effectiveness of this surgery, there have been 
limb volume reductions and successful connections of lymph vessels and veins, lymph 
nodes and veins, and multiple lymph vessels (Weiss et al., 2003; Becker et al., 2006; 
Baumeister, 2003a, 2003b; Koshima, 2000; Chang, 2010; Campisi et al., 2006). Surgical 
treatment of affected lymphedema sights is risky and very rarely a necessary consideration. 
If surgical treatment is considered, CDT is still a necessary adjunct and compression 
garments and Phase II maintenance is crucial (Warren et al., 2007). 
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6. Pharmacological, complementary integrative and alternative management 
Pharmaceutical approaches to lymphedema have shown that treatment with drugs, such as 
Diosmin and Coumarin, or dietary supplements alone is ineffective. Diuretics cannot 
effectively remove interstitial fluid from the tissues, but may ultimately result in 
dehydration, electrolyte imbalance, or tissue damage. However patients with a history of 
hypertension and cardiovascular disease should speak to a healthcare provider or doctor 
before stopping use of diuretics (Farrow, 2010b; Loprinzi, 1999; Taylor, 1993; Cotonat, 1989).  
Little research from studies has proved that all natural supplements are beneficial for 
lymphedema patients. Selenium has been proven to aide in lymphedema as a consequence 
of head and neck cancers. However, bromelain and American horse chestnut have not been 
studied for lymphedema related specific cases. Any natural supplements should be 
discussed with a physician prior to ingestion (Siebert et al., 2002; Micke et al., 2003; Bruns et 
al., 2004; Cirelli, 1962; Kelly, 1996; Gaby, 1995).  
Ongoing research has been presented in treatments such as cold laser, electrical stimulation, 
vibratory therapy, oscillation therapy, endermologie and aqualymphatic therapy and are 
done in combination with portions of CDT (Piller et al., 2010; Carati et al., 2003; Hafner et al., 
2005; Lawrence, 2008; Tidhar et al., 201; Omar et al., 2010; Jahr, et al., 2008). Acupuncture is 
shown to ease some cancer and treatment related symptoms such as fatigue, hot flashes, 
nausea, neuropathy, and muscular or joint pain, but no formal treatment has been devised 
from acupuncture (Farrow, 2010b).  
7. Conclusions 
Overall, lymphedema is a serious condition that requires timely intervention and 
appropriate therapy. The multidisciplinary approach is important to a patient at risk for 
lymphedema. It is important that early education on lymphedema be a standard of 
management and care for all patients. Prevention, screening, and measurement are all 
important for early detection of breast cancer related lymphedema. The conservative 
surgical approach minimizes a breast cancer patient’s long-term risk of lymphedema, as 
does hormonal therapy. Chemotherapy, on the other hand, may have risks associated with 
developing lymphedema after breast cancer.  
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